The Cancer Institute NSW Premier’s Awards for Outstanding Cancer Research is an annual event that celebrates excellence and innovation in cancer research. Seven awards were presented on Friday, August 22, to those leading the way in their field.
Dr Glen Reid, from the Asbestos Disease Research Institute, accepted one of the awards – the Excellence in Translational Cancer Research ($20,000) – on behalf of a team from:
The multidisciplinary team of scientists, clinicians and biotech experts from six organisations investigating malignant pleural mesothelioma (MPM), used tumour samples stored in the ADRI mesothelioma biobank, one of Australia’s largest repositories of tumour samples, to identify a consistent change in how a particular family of genes work in MPM that, when corrected, stops the cancer cells growing. This research has been rapidly brought to clinical trial stage, in less than three years.
The MesomiR-1 trial is the first to focus on MPM and Non-Small Cell Lung Cancer (NSCLC), for which few treatment options exist. The trial represents a new approach to therapy for these cancers.
Read more here: http://www.cancerinstitute.org.au/news-events/latest-news/2014-nsw-outstanding-cancer-researcher-of-the-year-announced
Jocelyn McLean joins the Asbestos Diseases Research Institute (ADRI), after many years of caring for patients having surgery for lung cancer, mesothelioma and benign conditions at Royal Prince Alfred Hospital. Utilising her knowledge and experience of patient and carer needs and drawing from current survivorship research and carer need research she provides sensitive telephone and face-to-face support for these people.
Call Jocelyn on 02 97679854 or Toll Free 1300 237 400
Or email: Jocelyn.McLean@sydney.edu.au
Quality of life in patients with Mesothelioma
The ADRI is running a study investigating ‘quality of life’ in patients diagnosed with mesothelioma. While we are aware that there is a high symptom burden in patients suffering from mesothelioma, we have little information on ‘quality of life’ in people living with this disease. By using questionnaires we try to get a more accurate picture of the impact of the disease and treatment on ‘quality of life’. Our study will look at how quality of life changes over time, and the impact of different types of treatment. We are also interested in learning more about psychological needs (anxiety and depression), and whether people are actually receiving the care that they need. How quality of life relates to other issues such as nutrition and functional (physical) ability, and relationships with inflammatory markers will also be studied in select hospitals.
For more information about this project, please contact Jason Fowler at email@example.com
The research leading to ADRI’s upcoming clinical trial has been recognised by the award of one of two best poster prizes at the recent WIN Symposium 2014 in Paris. The study describes the translational research leading to the new microRNA-based treatment approach for malignant pleural mesothelioma and non-small cell lung cancer, and was presented by Dr Glen Reid. The WIN symposium, with the theme this year of “WINning combinations for precision cancer medicine” had 400 delegates from around the world, and focused on breakthrough biomarker investigations and combined therapeutic approaches. More detail from the presentation and the conference can be found here.
Following on from last year’s breakthrough research into the role of microRNAs in malignant pleural mesothelioma, Dr Glen Reid has been awarded a $346,000 grant from the Cancer Council NSW to further ADRI’s research into microRNA-based replacement therapy.
One of just 16 applications funded this year, the project entitled “Developing a microRNA-based drug as a new treatment option for mesothelioma” will investigate in more detail ways in which targeted delivery of microRNAs can be used to inhibit tumour growth in pre-clinical models.
This work will be carried out together with scientists at the biotech company EnGeneIC, with whom ADRI have been collaborating for over two years.